Craig Hallum Issues Positive Forecast for Celcuity (NASDAQ:CELC) Stock Price

Celcuity (NASDAQ:CELC) had its price objective upped by Craig Hallum from $96.00 to $108.00 in a research note released on Thursday,Benzinga reports. The firm currently has a buy rating on the stock.

Other equities research analysts also recently issued reports about the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celcuity in a research report on Wednesday, October 8th. Leerink Partners increased their price target on Celcuity from $28.00 to $60.00 and gave the company an “outperform” rating in a research report on Monday, July 28th. Needham & Company LLC set a $95.00 target price on Celcuity in a research report on Monday, October 20th. Wall Street Zen cut Celcuity from a “hold” rating to a “sell” rating in a research report on Sunday, October 26th. Finally, Stifel Nicolaus increased their target price on Celcuity from $68.00 to $115.00 and gave the company a “buy” rating in a report on Thursday. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $91.00.

Celcuity Trading Up 7.8%

NASDAQ CELC traded up $6.68 on Thursday, hitting $92.68. 1,311,863 shares of the stock were exchanged, compared to its average volume of 730,620. The stock has a fifty day moving average price of $61.61 and a two-hundred day moving average price of $36.77. The firm has a market capitalization of $3.93 billion, a P/E ratio of -25.25 and a beta of 0.72. The company has a debt-to-equity ratio of 2.24, a quick ratio of 4.58 and a current ratio of 4.58. Celcuity has a 52-week low of $7.57 and a 52-week high of $94.06.

Celcuity (NASDAQ:CELC) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.92) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.13. The company had revenue of $0.15 million for the quarter. Research analysts forecast that Celcuity will post -2.62 EPS for the current fiscal year.

Institutional Investors Weigh In On Celcuity

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Ogorek Anthony Joseph NY ADV acquired a new position in Celcuity in the third quarter worth approximately $27,000. US Bancorp DE lifted its stake in Celcuity by 25.4% during the third quarter. US Bancorp DE now owns 706 shares of the company’s stock worth $35,000 after purchasing an additional 143 shares during the period. BNP Paribas Financial Markets raised its position in Celcuity by 78.9% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock valued at $35,000 after purchasing an additional 1,167 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of Celcuity by 211.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,549 shares of the company’s stock valued at $74,000 after purchasing an additional 3,766 shares during the last quarter. Finally, Avanza Fonder AB acquired a new stake in Celcuity in the third quarter worth $79,000. Institutional investors own 63.33% of the company’s stock.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.